Clinical Research Directory

Inclusion Criteria: * Prior diagnosis of Stage 0 to III breast cancer that is estrogen receptor negative, progesterone receptor negative with completion of definitive surgery, radiation therapy and/or chemotherapy. * Completion of chemotherapy or trastuzumab for \> six months and of radiation therapy for \> 2 months, as applicable and 5 years or less from completion of standard therapy. * Greater than 1 year from pregnancy, lactation. * Mammogram within the eight months prior to study enrollment that is not suspicious for breast cancer (ACR Class I-III). Exclusion Criteria: * Other current malignancy or metastatic malignancy of any kind. * Ongoing chemotherapy, radiation therapy, or other cancer-related treatment. * Subjects on Coumadin or other anticoagulants. * Subjects with breast implants. * Subjects who have had radiation to both breasts or who have undergone bilateral mastectomies. * Barriers to fine needle aspiration sampling of breast adipose tissue and/or parenchymal breast tissue, including breast implants, history of radiation to both breasts, bilateral mastectomies, and/or insufficient breast adipose/parenchymal tissue for adequate fine needle aspiration (FNA) sampling. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hypertension, or psychiatric illness/social situation that would limit compliance with study requirements. * Chronic use of omega 3 fatty acid concentrates or capsules within the 3 months prior to entry on the study or any other supplements that might interact with omega 3 fatty acid supplements. * Pregnant or nursing women. * Known sensitivity or allergy to fish. * Subjects on a standing regimen of full dose aspirin (greater than 325 mg/day), NSAIDs (nonsteriodal anti inflammatory drug) or NSAID-containing products.